Longitudinal analysis of circulating biomarkers to monitor advanced EGFR mutated (EGFR+) non-small cell lung cancer (NSCLC)
Pei Ni Ding(Camden and Campbelltown Hospitals), Tara L. Roberts(Camden and Campbelltown Hospitals), Joseph W. Po(Camden and Campbelltown Hospitals), Victoria Bray, David T. Lynch(Mayo Clinic in Arizona), Nicole Caixeiro(Camden and Campbelltown Hospitals), Therese M. Becker(Liverpool Hospital), Alison W. S. Luk(UNSW Sydney), Yafeng Ma(Camden and Campbelltown Hospitals), Paul de Souza(St. George Hospital)
Cited by 0
Related Papers
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k
HIN-200 Proteins Regulate Caspase Activation in Response to Foreign Cytoplasmic DNA
|Science|2009|822
AIM2 and NLRP3 inflammasomes activate both apoptotic and pyroptotic death pathways via ASC
|Cell Death and Differentiation|2013|507